RT Book, Section
A1 Myrianthefs, Pavlos M.
A1 Karabatsos, Elias
A1 Baltopoulos, George J.
A2 Hall, Jesse B.
A2 Schmidt, Gregory A.
A2 Kress, John P.
SR Print(0)
ID 1107719756
T1 Sepsis and Immunoparalysis
T2 Principles of Critical Care, 4e
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 9780071738811
LK accessmedicine.mhmedical.com/content.aspx?aid=1107719756
RD 2024/04/23
AB Current  paradigms  of  sepsis  include  both  pro-  and  anti-inflammatory  pathway  activation  to  different  degrees  and  at  different  phases  of  the  syndrome.Failure  to  recognize  and  understand  the  dynamic  changes  in  immune  response  in  sepsis  may  in  part  explain  the  failure  of  a  number  of  anti-inflammatory  drugs  and  biologics  studied  in  critically  ill  patients.The  anti-inflammatory  or  immunosuppressed  state  associated  with  sepsis  and  other  forms  of  critical  illness  is  often  protracted  and  places  patients  at  risk  for  complicating  nosocomial  infections  and  activation  of  latent  infections.When  clinically  significant,  the  anti-inflammatory  state  associated  with  sepsis  is  termed  immunoparesis  or  immunoparalysis.Cell  and  humoral  biomarkers  are  needed  to  properly  characterize  the  individual  patient’s  immune  status  to  guide  targeted  and  personalized  therapy  to  modulate  both  excessive  immune  stimulation  as  well  as  immune  suppression.